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P21-ACTIVATED KINASE-1 SIGNALING REGULATES TRANSCRIPTION OF 
TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR 
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Running title: PAK1 making in-roads into TF Pathway  
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Background: TF and TFPI, two primary 
components of the coagulation cascade, play 
important roles in non-homeostatic and 
pathological events. 
Results: PAK1 stimulates and represses the 
expression of TF and TFPI, respectively, and 
promotes procoagulant activity.  
Conclusion: PAK1 is identified as an important 
player in the coagulation processes. 
Significance: Targeting PAK1 might lead to a 
novel therapeutic strategy in the control of 
coagulation. 
 
ABSTRACT 
Tissue factor (TF) is a cell-surface glycoprotein 
responsible for initiating the coagulation 
cascade. Besides its role in homeostasis, studies 
have shown the implication of TF in embryonic 
development, cancer related events, and 
inflammation via coagulation-dependent and -
independent (signaling) mechanisms. Tissue 
factor pathway inhibitor (TFPI) plays an 
important role in regulating TF-initiated blood 
coagulation. Therefore, transcriptional 
regulation of TF expression and its physiologic 
inhibitor TFPI, would allow us to understand 
the critical step that control many different 
processes. From a gene profiling study aimed to 
identify differentially regulated genes between 
wild type (WT) and p21-activated kinase 1-null 
(PAK1-KO) mouse embryonic fibroblasts 
(MEFs), we found TF and TFPI are 
differentially expressed in the PAK1-KO MEFs 
in comparison to wild-type MEFs. Based on 
these findings, we further investigated in the 
present study the transcriptional regulation of 
TF and TFPI by PAK1, a serine/threonine 
kinase. We found that PAK1/c-Jun complex 
stimulates the transcription of TF and 
consequently, its procoagulant activity. 
Moreover, PAK1 negatively regulates the 
expression of TFPI and thus, additionally, 
contributes to increased TF activity. For the 
first time, this study implicates PAK1 in 
coagulation processes, through its dual 
transcriptional regulation of TF and its 
inhibitor. 
 
INTRODUCTION 
Tissue factor (TF) (also known as F3, 
coagulation factor III or thromboplastin), a 47-
KDa transmembrane glycoprotein and the primary 
initiator of the coagulation cascade (1), plays a 
critical role in homeostasis and thrombosis (2). It 
functions as a high-affinity receptor for the serine 
proteases factors VII and VIIa. The resulting TF-
VIIa complex activates both factors IX and X 
leading to thrombin generation and fibrin 
formation (1). TF-induced coagulation is regulated 
by a specific inhibitor termed Tissue factor 
pathway inhibitor (TFPI). The mechanism of 
inhibition by TFPI involves its binding first to 
factor Xa and then to the VIIa/ TF complex (1). 
In the last few years, it has become evident that 
TF is involved in various other (patho) 
physiological processes apart from homeostasis, 
such as embryonic development, transmision of 
signals, promotion of cell migration, adhesion, 
tumor initiation, growth, and inflammation (3). 
Concomitantly, TFPI, the physiologic inhibitor of 
TF, has also been widely implicated in the 
regulation of those non-homeostatic functions of 
TF (4). TF is essential for the normal embryonic 
development and its absence could lead to a 
defective vessel development and embryonic death 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M112.404061The latest version is at 
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in mice (5). The expression of TF is deregulated in 
many cancers, and this up-regulation is often 
linked with  aggressive malignancies (6) and 
increased tumor growth (7). Moreover, expression 
of TF amplifies the inflammatory reaction in 
patients with sepsis (8,9).  
TF contributes to pathologies by activation of 
the coagulation cascade (proteolysis dependent 
signaling) as well as by coagulation-independent 
(proteolysis independent) signaling events via the 
cytoplasmic domain of TF (3,10). Thus, TF might 
not only function as the initiator of coagulation but 
also as a transmembrane signaling receptor which 
regulates angiogenesis, tumor growth, metastasis, 
and inflammation. Therefore, understanding the 
transcriptional regulation of TF expression and its 
inhibitor, TFPI, would appear to be a critical step 
in the control of many different processes.  
The PAKs are serine/threonine kinases that 
were originally identified as binding partners and 
downstream effectors of Cdc42 and Rac1 in actin 
reorganization and cell migration (11). PAK1, the 
best-characterized member of the PAK family, is 
activated by the p21ras-related proteins Cdc42 and 
Rac1 (11), but also by a wide variety of 
extracellular signals (12) which promote PAK1’s  
auto-phosphorylation and stimulation of its kinase 
activity (13). PAK1 kinase activity has been 
implicated in a wide variety of cellular processes, 
including, cell motility, survival and proliferation, 
morphogenesis, cytoskeleton remodeling, and 
transcription (14). In addition to its well-
characterized kinase activity, the PAK1 pathway 
also affects nuclear events in a profound manner 
(15-17) and also regulates the transcription of 
target gene chromatin (18-20).  
During a previous gene profiling study that 
includes wild-type (WT) and knock-out PAK1 
(PAK1-KO) mouse embryonic fibroblasts (MEFs), 
we identified TF and TFPI to be down- and up-
regulated, respectively, in the PAK1-KO MEFs in 
comparison to its wild type controls (RK, 
unpublished data), suggesting that PAK1 might 
regulate the expression of TF and TFPI. Given the 
involvement of TF, and TFPI, in several 
pathological and physiological events, the present 
study was undertaken to investigate the genomic 
regulation of TF and TFPI by PAK1 signaling. To 
date, nothing is known about the regulation of TF 
expression by PAK1 in cancer cells. We 
discovered, for the first time, that PAK1 signaling 
stimulates and inhibits the transcription of TF and 
TFPI, respectively, and modulates the coagulation 
process. 
 
EXPERIMENTAL PROCEDURES 
Cell culture, Antibodies and Reagents. HeLa, 
HEK 293T and MDA-MB-231 cells were obtained 
from American Type Culture collection (ATCC), 
and cultured in Dulbecco’s modified Eagle’s 
medium/F12 supplemented with 10% fetal bovine 
serum and 1X antibiotic-antimycotic solution in a 
humidified 5% CO2 at 37°C. PAK1 WT and KO 
mouse embryonic fibroblasts (MEFs) have been 
described earlier (21). Sources of antibodies were 
as follows: mouse anti-phospho-PAK1 (Thr 212) 
(Sigma-Aldrich, St. Louis, MO), Rabbit anti-
PAK1 (Bethyl laboratories, Montgomery, TX), 
mouse anti-Tissue Factor (10H10) (Novus 
Biologicals, Littleton, CO), mouse anti-vinculin 
(Sigma-Aldrich, St. Louis, MO), rabbit anti-c-JUN 
(Santa Cruz Biotechnologies, Santa Cruz, CA), 
mouse anti-myc Tag (9B11) (Cell Signaling 
Technology, Danvers, MA), and mouse anti-Flag 
M2 (Sigma-Aldrich, St. Louis, MO). Normal 
mouse IgG, and rabbit IgG were from Sigma-
Aldrich (St. Louis, MO). All primary antibodies 
were used as according to manufacturer’s 
instructions. Horseradish peroxidase-conjugated 
secondary antibodies were from GE Healthcare 
(Piscataway, NJ), and enhanced 
chemiluminescence (ECL) reagents were from 
Amersham Biosciences (Piscataway, NJ). The 
blocking antibody for human Tissue factor TF8-
5G9 was a generous gift of Dr. James H. 
Morrissey (University of Illinois). 
Expression vectors, recombinant proteins, siRNAs, 
and transfections. Expression vectors encoding 
PAK1-myc, PAK1 T423E, and PAK1 K229R 
were generously provided by Jonathan Chernoff 
(Fox Chase Cancer Center, Philadelphia, PA) and 
have been previously described (22), pCDNA3.1-
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PAK1, and GST-PAK1 have been described 
previously (23). pcDNA-c-JUN-Flag (c-JUN-Flag) 
and GST-c-JUN have been used previously (24). 
The dominant negative mutant of c-JUN was a 
generous gift from Dr. Powell H. Brown (National 
Cancer Institute, NIH, Rockville, Maryland, MD) 
and has already been described (25). All GST 
recombinant proteins were expressed in E. coli 
strain BL21 (DE3) (Stratagene, La Jolla, CA) and 
subsequently purified using the Glutathione 
Sepharose 4B batch method (GE Healthcare, 
Piscataway, NJ). In vitro translation was 
performed using The TNT® Quick Coupled 
Transcription/Translation Systems (Promega, 
Madison, WI). Plasmid transfections were carried 
out using FuGENE HD Transfection Reagent 
(Roche Applied Science, Indianapolis, IN) 
according to manufacturer’s instructions. When 
needed, after 24h of transfection, cells were serum 
starved for another 24 hours, before serum 
stimulation for the indicated times. Specific 
siRNAs targeting human PAK1 or control siRNAs 
were obtained from Cell Signaling Technology 
(Danvers, MA). The transfection of siRNA was 
performed twice at 24-hour intervals with 
Oligofectamine
 
TM
 reagent (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s protocol. 24 
hours after the second round of transfection, cells 
were serum starved for 24 hours, before serum 
stimulation for the indicated times. 
Microarray Gene Expression Assays and Analysis. 
Microarray gene expression assays and data 
analysis have been described previously (26). The 
datasets of differentially expressed genes between 
PAK1 WT and KO MEFs were analyzed using 
Ingenuity Pathway Analysis to discover 
relationships between the genes as well as their 
association with various processes and disorders 
(Motwani et al, unpublished). The Fisher’s exact 
test was used to identify significant functions and 
pathways represented within the respective 
datasets.  
Quantitative Real Time PCR (qPCR). Total RNA 
was isolated from cultured cells using TRIzol 
reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s protocol, and two micrograms 
of extracted RNA was converted to cDNA using 
the SuperScriptTM III First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA). 
The resultant cDNA was subjected to qPCR by 
using the iQTM SYBR® Green Supermix (Bio-
Rad Laboratories, Hercules, CA) on an iCycler 
iQ™ Real-Time PCR Detection System (Bio-Rad 
Laboratories). The values for specific genes were 
normalized to human actin or mouse 18S 
housekeeping controls. Mean values are displayed 
± standard deviations. The primers used were: 
hACTIN_F: 5’-TCC CTG GAG AAG AGC TAC 
GA-3’, hACTIN_R: 5’-GTA CTT GCG CTC 
AGG AGG AG-3’, hTF_F: 5’-GCC CGG TAG 
AGT GTA TGG GCC AG-3’, hTF_R: 5’-GCT 
CTG CCC CAC TCC TGC CTT-3’, hTFPI_F: 5’- 
AGT ATG GTG GAT GCC TGG GCA ATA-3’, 
hTFPI_R: 5’- ACC TGG AAA CCA TTC GGA 
CCA TCT-3’, m18S_F: 5’-CCG GAG CTA GGA 
ATA ATG GA-3’, m18S_R: 5’-CCC TCT TAA 
TCA TGG CCT CA-3’, mTF_F:5’-AGA ACA 
CCC CGT CGC GCT TG-3’,  mTF_R: GCT CTC 
CGC AAC AGT GCC GT-3’, mTFPI_F: 5’- TGT 
TGC TTA GCC TTG TTC CCG AGT-3’, and 
mTFPI_R: TGC TTT GCA TGG ACC ATC ATC 
TGC-3’. All qPCR primers were synthesized in 
Sigma-Aldrich (St. Louis, MO).  
Western Blot and Immunoprecipitation. Protein 
extracts were prepared by lysing the cells in the 
RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 
1% Nonidet P-40, 0.25% sodium deoxycholate, 
150 mM NaCl, 1 mM EDTA, 1×protease inhibitor 
cocktail (Roche Applied Science, Indianapolis, 
IN), and 1× phosphatase inhibitor cocktail I and II 
(Sigma-Aldrich, St. Louis, MO), and protein 
concentrations were determined using Bio-Rad 
DC Protein Assay reagents (Bio-Rad Laboratories, 
Hercules, CA). Cell extracts were then resolved by 
SDS-PAGE, transferred to nitrocellulose 
membranes, and incubated with the indicated 
antibodies. Detections were performed using the 
ECL reagents. For immunoprecipitation (IP) 
analysis, total 1 mg of protein materials was 
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incubated with 1 µg of primary antibody overnight 
at 4 °
 
C on a rocket platform, followed by 
incubation with total 50 µl of protein A/G PLUS-
agarose (Santa Cruz Biotechnology, Santa Cruz, 
CA) or Trueblot IP beads (eBioscience, San 
Diego, CA) for 2 h at 4 °C. The 
immunoprecipitates were collected by 
centrifugation in a microcentrifuge at 6000 rpm 
for 5 min. The supernatant was discarded, 
whereupon the pellet was washed with Nonidet P-
40 buffer (NP40 lysis buffer) (50 mM Tris-HCl, 
pH 8.0, 0.5 % Nonidet P-40, 10 % Glycerol, 150 
mM NaCl, 2 mM MgCl2
 
, and 1 mM EDTA), with 
protease inhibitors for three to five times and then 
dissolved in a sample buffer for SDS-PAGE. 
GST pull-down assays. The GST pull-down assays 
were performed by incubating equal amounts of 
GST or GST fusion protein immobilized to 
glutathione-Sepharose beads with in-vitro 
translated 35S-labeled protein, in a 400 µl reaction 
volume. The mixtures were incubated for 2h at 4 
°C and washed three to six times with NP40 lysis 
buffer. Bound proteins were eluted with 2x SDS 
buffer, separated by SDS-PAGE and visualized by 
autoradiography. The transferred protein on the 
blot was visualized using Ponceau S stain. 
Chromatin Immunoprecipitation (ChIP) and re-
ChIP assays. The ChIP assays were performed as 
described previously (27). Briefly, approximately 
106 cells were treated with 1% formaldehyde (final 
concentration) for 10 min at 37°C to cross-link 
histones to DNA and washed twice with 
phosphate-buffered saline containing protease 
inhibitors cocktail. Cells were lysed by sonication 
and immunoprecipitated with specific antibodies. 
The immunoprecipitates were washed, the DNA 
was eluted off the beads, and purified DNA 
(phenol-chloroform extraction) was subjected to 
PCR. PCR primers for ChIP assays for TF and 
TFPI promoters are provided in supplemental 
Tables 1 and 2, respectively. For re-ChIP assays, 
the first ChIP using a PAK1 antibody (Bethyl 
laboratories) was followed by a second ChIP using 
a c-JUN antibody (Santa Cruz biotechnology). 
Quantification of the bands amplified by PCR was 
done using ImageJ software. 
Electrophoretic Mobility Shift Assay. Nuclear 
extracts were prepared using a Nonidet P-40 lysis 
method (28). EMSA for the binding of different 
transcription factors was performed using the 
annealed and [γ-32P] ATP end-labeled 
oligonucleotides in a 20-µl reaction mixture for 15 
min at 20 °C.  Samples were run on a 
nondenaturing 5% polyacryalmide gel and imaged 
by autoradiography. Supershift EMSAs were 
performed by incubating the nuclear extracts with 
2µg of either the PAK1 (Bethyl laboratories, 
Montgomery, TX) or the c-JUN (Santa Cruz 
Biotechnology, Santa Cruz, CA) antibody for 1 
hour before the addition of the radiolabeled 
oligonucleotides. Oligonucleotides used are listed 
in supplemental Table 3. 
Tissue Factor procoagulant activity (PCA) assay. 
TF activity, measured as the amount of FXa 
generated, was determined using the AssaySense 
Human TF Chromogenic Activity Assay Kit 
(AssayPro) with minor modifications, according to 
Drake TA et al (29). Cells were detached by brief 
exposure to Trypsin-EDTA, washed three times 
with DMEM/F12 and resuspended in DMEM/F12 
at 4 x 105 cells/ml. For blocking cell-surface 
expressed TF, anti-TF mAb TF8-5G9 (10µg/ml) 
was incubated with 1ml of the corresponding 
intact cell suspensions for 15 min at 37 °C, washed 
three times with DMEM/F12 and divided into two 
equal portions. One portion was resuspended in 
Hepes-saline buffer (25mM Hepes, 0.85% NaCl, 
pH 7.4) and kept at 4 °C before assay of intact cell 
surface TF activity. The other portion was lysed 
by freezing the cell suspension at -70 °C for 15 
min and solubilization with 15mM octyl-β-D-
glucopyranoside at 37 °C for 15 minutes for assay 
of total  TF procoagulant activity. Identical 
aliquots of intact  (cell surface TF PCA) and lysed 
cells (total TF PCA) were assayed, following the 
manufacturer’s recommendations, and the amount 
of FXa generated was determined by reading the 
absorbance at 405nm every 2 minute for 20 
minutes, using a kinetic 96 well microplate reader 
(Synergy-H1 Hybrid Reader, Biotek). 
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RESULTS AND DISCUSSION 
PAK1 up regulates the expression of Tissue 
factor 
Microarray gene profiling study that includes 
wild-type (WT) and PAK1- knockout (KO) mouse 
embryonic fibroblasts (MEFs) was performed to 
identify the new genes or pathways that are 
influenced by PAK1 (RK, unpublished data). 
When the statistically significant differentially 
expressing genes were studied using Ingenuity 
Pathway Analysis, a total of 16 genes assigned to 
thrombosis were differentially expressed in 
between wild-type and PAK1-KO MEFs (Table 
1). These findings raise a new interesting line of 
research and for the first time; introduce PAK1 as 
a possible new regulatory player in thrombosis.  
In the microarray analysis, TF, the primary 
initiator of the coagulation cascade, was 
remarkably found to be differentially expressed 
between both cell lines. The expression of TF was 
2.53-fold down-regulated in the PAK1-KO 
compared to wild-type MEFs (Table 1). Consistent 
with the above data, RT-quantitative PCR 
confirmed that TF expression was down-regulated 
in the PAK1 KO MEFs as compared with its wild-
type counterparts (Fig.  1A), positioning TF as a 
potential downstream target of PAK1. Through its 
impact on the coagulation cascade and cellular 
signaling, TF acts as an important regulator of 
vascular development, several cancer-related 
processes, such as hypercoagulability, 
angiogenesis and metastasis, and inflammation 
(3). Therefore, the knowledge of its transcriptional 
regulation will be of great scientific interest. 
A previous study already implicated PAK1 in 
the regulation of TF expression in PASMCs (30). 
These authors observed that PAK1 is involved in 
thrombin signaling in PASMC and regulates the 
expression of TF by activating p38MAPK, PDK1 
and PKB, and thus, PAK1 could play a role in 
vascular remodeling. Given the stablished 
connection between malignancy and 
hypercoagulant states (31) and PAK1’s role in 
malignant processes (32), as well as the linkage of 
TF with cancer related processes (6,33), the 
possible role of PAK1 as a modulator of 
thrombosis in cancer cells was viewed of high 
interest for a more in depth study. To date, nothing 
is known about the regulation of TF by PAK1 in 
cancer cells. Further studies in the human 
epithelial cancer cell lines, such as HeLa and 
MDA-MB-231, demonstrated that the serum 
induction of PAK1 activity induced up regulation 
of TF protein as well as mRNA levels (Fig.  1B 
and C), suggesting a role of PAK1 in the 
regulation of TF expression.  
PAK1 is required for TF up regulation by serum 
Since the induction of TF by serum has been 
well described (34), to further demonstrate the 
implication of PAK1 in the regulation of TF 
expression by serum, we examined the effect of 
PAK1 down regulation conditions on TF 
expression. As shown in Fig. 2A, PAK1 down 
regulation by siRNA transfection in HeLa cells 
compromised the ability of serum to stimulate TF 
protein as compared to cells transfected with a 
control siRNA. The induction of TF mRNA 
expression was also analyzed in wild-type and 
PAK1-KO MEFs (Fig.  2B). The results show that 
the serum induction of TF mRNA observed in the 
wild-type MEFs was almost completely abolished 
in PAK1-KO MEFs, highlighting the significance 
of PAK1 in the regulation of TF expression.  
We next examined whether the kinase activity 
of PAK1 is essential for the regulation of TF 
expression. To test this, we analyzed the effect of 
a dominant-negative K229R and catalytically 
active T423E PAK1 mutants (22,35) on the 
expression of TF by serum (Fig.  2C). Transient 
transfection of HeLa cells with the catalytically 
active T423E PAK1 mutant resulted in a superior 
stimulation of TF protein and mRNA by serum as 
compared to the control cells (Fig.  2C). On the 
other hand, cells expressing the kinase-dead 
K229R PAK1, partially suppressed the ability of 
serum to stimulate TF protein and mRNA 
expression levels (Fig.  2C). These results 
demonstrate the significance of PAK1 expression 
and activity in the induction of TF expression by 
serum.  
PAK1 recruitment onto TF promoter 
The previously observed nuclear localization of 
PAK1 (18), as well as its already reported 
modulatory effect in the transcription of some 
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genes, such as nuclear factor of activated T-cell 
(NFAT1) and the phosphofructokinase-muscle 
isoform (PFKM) (18), prompted us to investigate 
the direct genomic regulation of TF transcription 
by PAK1 in cancer cells. 
Therefore, we examined the recruitment of 
PAK1 in the promoter of TF using a ChIP- based 
promoter walk assay. To this end, cross-linked 
chromatin from HeLa cells was 
immunoprecipitated with an anti-PAK1 antibody 
or IgG, and then PCR-amplified using primers 
designed against about every 400-base pair (bp) 
region of the TF promoter (Fig. 3A). Results from 
Fig. 3B show that PAK1 was recruited to the TF 
promoter at a region encompassing -666 to -1529 
bp from the transcription start site (TSS). In an 
attempt to narrow down the region of the TF 
promoter in which PAK1 was recruited, regions 3 
and 4, which are positive for PAK1 recruitment, 
were subdivided further into two smaller regions, 
of about 200 bp each. New primers encompassing 
these regions were designed, and the same purified 
eluted DNA was PCR-amplified using these 
primers (Fig.  3C). We discovered that PAK1 was 
indeed recruited to the regions 3.2 to 4.2, but not 
to the region 3.1 (Fig.  3C). Our results indicate, 
for the first time, that PAK1 is able to specifically 
bind to the TF promoter region, demonstrating that 
TF is a target of PAK1. 
Involvement of c-JUN transcription factor in 
PAK1- mediated TF up regulation  
Since PAK1 lacks transcriptional activity but is 
able to induce TF expression, we next 
hypothesized that PAK1 might be co-recruited to 
the TF promoter along with a transcription factor, 
which could be responsible for the direct 
stimulation of TF transcription. For this reason, we 
next performed a sequence analysis of the TF 
promoter-PAK1 interacting regions (regions 3-4, 
see Fig. 3B) using the Promo 3.0 software (36) to 
identify the putative binding sites for transcription 
factors that might be responsible for the PAK1-
mediated stimulation of TF transcription. The 
complete list of the resulting transcription factor 
binding sites is presented in Table 2. We found 
that TF promoter harbors binding sites for some 
transcription factors already involved in cell 
growth, proliferation and cancer related signaling 
events. These included TCF-4E, GATA-1, TFII-I, 
PXR-1: RXR-alpha, c-ETS-1, or AP-1/c-JUN (37-
42). Similarly, the involvement of both PAK1 and 
TF in such processes has been well stablished 
(13,33). Therefore the above mentioned 
transcription factors appear to be good candidates 
for PAK1-mediated TF transcriptional up 
regulation.  
To assess the above possibility, we examined 
the direct recruitment of these transcription factors 
to the TF promoter by electrophoretic mobility 
shift assay (EMSA) (Fig. 4A). To this end, we 
designed double-stranded oligonucleotides, 
containing the binding site(s) for each 
transcription factor(s), that were radiolabeled, and 
the binding of each transcription factor was 
analyzed using nuclear extracts from control and 
serum-stimulated HeLa cells. After electrophoresis 
and autoradiography, we detected the formation of 
DNA-protein complexes with the oligonucleotides 
containing binding sites for AP-1/c-JUN as well as 
TFII-I binding site b among the tested 
transcription factors (Fig. 4A). In addition, the 
observed complex was induced in serum-
stimulated HeLa cells compared to non-stimulated 
cells, only when using the specific 
oligonucleotides for AP-1/c-JUN binding site (Fig. 
4A), suggesting that PAK1-serum stimulated 
signaling uses AP-1/c-JUN to induce TF 
transcription. Accordingly, results from Fig.  4B, 
using nuclear extracts from control and serum-
stimulated HeLa (left panel) or MDA-MB-231 
cells (right panel) revealed that the formation of 
AP-1/c-JUN - DNA complex(s) at the TF 
promoter was completely abolished using an 
oligonucleotide containing the putative binding 
site mutated, confirming the presence of AP-1/c-
JUN. In addition, the observed complex could be 
highly inhibited, especially under serum-induced 
conditions, in the presence of an anti-c-JUN 
antibody, as well as in the presence of an anti-
PAK1 antibody, but not with a control 
immunoglobulin IgG antibody, suggesting the co-
existence of PAK1- and c-JUN/DNA complex(s). 
However, the presence of an anti-c-JUN antibody 
failed to exhibit the appearance of a super-shifted 
band, probably due to inefficient blocking of the 
recognition site for c-JUN in the DNA sequence 
and/or antibody-specific reasons.  
To gain a deeper insight into the molecular 
mechanism involved in c-JUN regulation of TF 
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expression, we next analyzed the in vivo 
recruitment of c-JUN to the TF promoter by 
chromatin immunoprecipitation (ChIP), using 
cross-linked chromatin from HeLa cells. We found 
the recruitment of c-JUN onto the region 3 of the 
TF promoter (Fig 4C). This is in agreement with 
the Promo 3.0 sequence analysis of the TF 
promoter-PAK1 interacting DNA region, which 
indicates this region comprises the binding site for 
c-JUN.  
The regulation of TF gene expression by c-JUN 
has been demonstrated in human monocytic and 
endothelial cells (43,44), as well as in cultured 
fibroblasts (45). However, the binding region of c-
JUN reported in these studies (located at a region 
around -200 to -220 bp, relative positions to the 
transcription start site (43-45)) is different from 
the one detected in the present study (-1450 bp, 
relative to the transcription start site). On the other 
hand, a previous report located elements required 
for serum and phorbol miristate acetate (PMA) 
induction of TF promoter in HeLa cells in a region 
between -96 and +121 bp, from a total region 
analyzed of 300 bp relative to the transcription 
start site (46). This region lacks any AP1/c-JUN 
binding site, but it is possible, however, that c-
JUN could account for the induction of TF gene 
transcription by serum in HeLa cells in a different 
region than the analyzed in the previous study (46)  
as compared to results obtained in the present 
study. The apparent controversy between different 
results could be explained by the fact that the TF 
gene is expressed in a cell type-specific manner 
(29). Moreover, our results suggest that not only 
the expression of TF appears to be mediated by 
distinct regions of the TF promoter in different cell 
types, but also, the induction in response of 
different stimuli can be mediated by distinct 
regions of the promoter in the same cell type. 
Results from Fig.  4B, as well as the fact that c-
JUN is recruited to the TF promoter region 3 (R3) 
(Fig.  4C), suggest that both PAK1 and c-JUN 
could be co recruited at the same region onto the 
TF promoter. To determine whether the PAK1/c-
JUN complex associates to the same region onto 
the TF promoter, a sequential double-ChIP 
analysis using the indicated antibodies was 
performed. We found that indeed, PAK1 and c-
JUN are co-recruited onto the c-JUN-TF promoter 
interacting region R3 (Fig.  4D), demonstrating the 
co recruitment of both proteins onto the TF 
promoter.  
To further demonstrate the importance of c-
JUN in PAK1-mediated TF up regulation, HeLa 
cells were co-transfected with the catalytically 
active mutant of PAK1 (T423E), and with a 
dominant negative mutant of c-JUN (TAM 67) 
that can repress its transcriptional activity (25). 
The cells were induced with serum for the 
indicated times, prior to the analysis of TF 
expression by qPCR. The presence of a dominant 
negative mutant of c-JUN partially suppressed the 
ability of the catalytically active mutant of PAK1 
to stimulate TF mRNA expression after serum 
induction (Fig. 4E), confirming the involvement of 
c-JUN in the regulation of TF expression by 
PAK1. 
PAK1 physically interacts with c-JUN. 
It has been previously reported that PAK1 
activates JNK, resulting in the phosphorylation 
and activation of c-JUN (47). However, our 
findings that PAK1 and c-JUN are co recruited 
onto the TF promoter raises the possibility of 
physical interaction between them. To test this 
notion, HEK293T cells were co-transfected with 
expression vectors encoding Flag-tagged c-JUN 
and Myc-tagged PAK1, and protein extracts were 
subjected to the sequential 
immunoprecipitation/Western blot (WB) analysis.  
Results from Fig. 5A show that, indeed, 
exogenously expressed Flag-c-JUN but not control 
IgG could be coimmunoprecipitated with Myc-
PAK1, suggesting that the two proteins interact in 
vivo. In addition, similar interaction was observed 
between PAK1 and c-JUN at the endogenous 
protein level in HeLa cells (Fig.  5B). To 
determine whether PAK1 directly binds to c-JUN, 
we next performed in vitro GST pull- down assays 
using 35S-labeled, in vitro-translated c-JUN protein 
and full-length GST-PAK1 fusion protein, as well 
as 35S-labeled, in vitro-translated PAK1 protein 
and full-length GST-c-JUN fusion protein, and 
found that 35S-labeled c-JUN and 35S-labeled 
PAK1 strongly bound to GST-PAK1 and GST-c-
JUN proteins respectively (Fig.  5C and D). These 
findings demonstrate that PAK1 physically 
associates with c-JUN both in vivo and in vitro. It 
is noteworthy that PAK2 is also shown to bind and 
phosphorylate c-JUN modulating its activity (48). 
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Given the similarity in the phosphorylation 
recognition motifs of PAK1 and PAK2, these 
results suggest that PAK1 interaction with c-JUN 
promotes its transcriptional activation and leads to 
induction of TF expression. 
 
PAK1 stimulation regulates the procoagulant 
activity of Tissue factor. 
To investigate the possibility of PAK1 
involvement in the coagulation cascade triggered 
by TF, we analyzed the TF activity, as means of its 
ability to activate Factor X (FX) to FXa. The 
amount of FXa generated was quantitated using a 
highly specific FXa substrate releasing a yellow 
para-nitroaniline (pNA) chromophore. The change 
in absorbance of the pNA at 405 nm is directly 
proportional to the TF enzymatic activity. HeLa 
cells transiently over-expressing the dominant-
negative K229R or catalytically active T423E 
PAK1 mutants, or control cells (empty vector) 
stimulated or not with serum for 3 hours were used 
for these experiments (Fig.  6).  
The corresponding intact cell suspensions were 
incubated with either control or anti-TF antibody 
for 15 min at 37°C and then washed to remove 
unbound antibody before cells were either lysed 
(for assay of total TF activity) or collected (for 
assay of cell surface TF activity), and the TF 
activity measured. As previously reported (49), 
intact HeLa cells expressed very little cell surface 
TF activity compared to the total TF activity in 
disrupted cells (data not shown). In addition, the 
presence of the TF blocking antibody was able to 
reduce <5% of the total activity (data not shown), 
thus indicating that the majority of TF in HeLa 
cells was expressed intracellularly, which is in 
agreement with previous reports (49). The 
presence of an intracellular pool may be 
particularly important because it is likely to be 
protected from extracellular inhibitors of TF. 
Furthermore, previous studies have found that a 
substantial portion of TF is not active on the 
surface of unperturbed cells, and have suggested 
that much of the TF is encrypted on the cell 
surface (50). Therefore, to further verify the 
implication of TF in the generation of FXa, the 
experiment was performed in the absence of FVII. 
This approach completely blocked all the activity 
(data not shown), thus demonstrating that the 
results obtained were entirely due to TF activity.  
In order to gain insight into the ability of PAK1 
to induce TF procoagulant activity, we monitored 
the ability of the endogenously expressed TF to 
enhance the specific proteolytic activation of FX 
to FXa during the whole assay (Fig.  6A and B). 
This is achieved through the constant annotation 
of the change in absorbance of the released 
chromophore pNA at 405 nm.  A clear increase in 
the TF procoagulant activity during the whole 
analysis was observed after serum treatment of the 
control and T423E PAK1 expressing cells, and 
this induction was more notable in cells expressing 
the catalytically active form of PAK1, T423E (Fig.  
6A ). On the contrary, serum was unable to further 
induce any TF activity in cells expressing the 
dominant negative PAK1 mutant (K229R) (Fig.  
6B). 
Active TF was determined from the standard 
curves generated, at two different time points (10 
and 20 minutes), using known concentrations of a 
recombinant human TF preparation, and expressed 
as pM of TF per number of cells (Fig. 6C). We 
found that control cells as well as catalytically 
active mutant PAK1 (T423E) cells showed a 
higher level of active TF after serum stimulation. 
Moreover, cells expressing the catalytically active 
PAK1 (T423E), showed even a higher level of 
active TF in serum stimulation conditions, as 
compared to control cells. However, the levels of 
active TF remained without any change in cells 
transiently transfected with the kinase dead mutant 
of PAK1 (K229R) (Fig.  6C), thus highlighting the 
implication of PAK1 activation in the control of 
TF coagulation activity. Together, these results 
implicate PAK1 signaling acts as a modulator of 
the coagulation protease cascade, by playing a role 
in the modulation of TF ability to activate FX.  
PAK1 recruitment onto TFPI promoter and 
modulation of its expression 
The above results demonstrate the significance 
of PAK1 signaling in the coagulation cascade 
triggered by TF. Interestingly, the natural inhibitor 
of the TF-mediated coagulation, Tissue Factor 
Pathway inhibitor (TFPI), was also found to be 
differentially expressed between wild-type and 
PAK1-KO MEFs (Table 1). PAK1-KO MEFs 
showed a 3.46 fold up regulation of TFPI 
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compared to wild-type MEFs, suggesting a 
possible negative regulation of TFPI expression by 
PAK1. 
RT-quantitative PCR analysis confirmed the up 
regulation of TFPI in the PAK1- KO cells as 
compared with its wild-type counterparts (Fig.  
7A). Furthermore, serum induction of PAK1 in 
HeLa and MDA-MB-231 human cell lines led to 
down regulation of TFPI mRNA expression (Fig.  
7B and C, respectively), suggesting that PAK1 can 
negatively modulate the expression of TFPI. 
Similar to TF, the expression of TFPI has also 
been reported to be modulated by serum (51). 
Hence, further studies were designed to 
demonstrate the significance of PAK1 signaling in 
the down regulation of TFPI expression. To this 
end, we analyzed the expression of TFPI mRNA 
in PAK1-KO MEFs or wild-type MEFs under 
serum stimulation conditions. We found a down 
regulation of TFPI mRNA levels by serum 
stimulation in the wild-type MEFs, and this down 
regulation was not only compromised in the serum 
stimulated PAK1-KO MEFs, but we observed 
instead a transient up regulation of TFPI mRNA 
expression levels in these cells, suggesting that 
PAK1 may be essentially involved in the 
repression of TFPI expression. 
We next investigated the importance of PAK1 
kinase activity in the regulation of TFPI 
expression. We analyzed the effect of the 
dominant-negative K229R and catalytically active 
T423E PAK1 mutants (22,35) on TFPI mRNA 
expression after serum induction (Fig.  7E). As 
expected, serum induction of cells overexpressing 
a kinase-dead PAK1 mutant (K229R) resulted in a 
progressive up regulation of TFPI mRNA 
expression, but no stimulation of TFPI mRNA 
levels was observed in those cells expressing the 
catalytically active PAK1 mutant (T423E).  
Results from Fig. 7 D and E suggest that PAK1 
expression and activation negatively regulates 
TFPI expression at the transcriptional level. To 
further strengthen this hypothesis, we next 
explored the recruitment of PAK1 to the promoter 
of TFPI using a ChIP-based promoter walk assay 
in cross-linked chromatin from HeLa cells 
immunoprecipitated with an anti-PAK1 antibody 
or IgG control antibody. A region of the human 
TFPI promoter of approximately 1700 base pairs 
(+25 to -1653 bp relative positions from the TSS) 
was analyzed by PCR using primers designed 
about each 400 bp (Fig.  7F). As shown in Fig. 7G, 
ChIP results showed the recruitment of PAK1 onto 
the TFPI promoter to a region encompassing -798 
to -1198 bp from the TSS, named Region 3 (R3). 
In summary, results from Fig. 7 demonstrates, for 
the first time, that PAK1 is recruited to the TFPI 
promoter and that PAK1 acts as a negative 
modulator of TFPI expression.  
Balanced levels of TF and TFPI are essential to 
maintain normal homeostasis. In this regard, the 
ability of PAK1 to up regulate TF expression, and 
down regulate TFPI expression places PAK1 as a 
new key molecule involved in the deregulation of  
normal homeostasis. In agreement with the results 
presented here, previous work from Diebold et al 
demonstrates the expression of PAK1 in the media 
of remodeled pulmonary vessels from patients 
with pulmonary vasculopathy and its implication 
in vascular remodeling by thrombin signaling in 
pulmonary artery smooth muscle cells (PASMCs) 
(52). Future studies, with the use of smooth 
muscle cells are guaranteed in order to better 
elucidate the role of PAK1 in thrombosis. From 
another point of view, given the role of PAK1 as a 
central signaling transducer and the emerging 
functions of TF, as well as of TFPI in different 
signaling events apart from homeostasis (53,54), 
our findings open a new transcriptional regulatory 
axis that could be highly relevant not only in 
coagulation, physiological signaling pathways, but 
also in several malignant processes. 
In summary, we provide here a novel 
regulatory mechanism of TF expression and 
procoagulant activity in epithelial cancer cells by 
PAK1-c-JUN complex. Furthermore, PAK1 is 
able to bind to the TFPI promoter, and negatively 
regulates its expression, presumably releasing the 
inhibition of the TF-FVIIa complex from TFPI, 
and in-turn, contributing to a hypercoagulant state 
(Fig.  7H). Our working model provides a novel 
function for PAK1 in the control of coagulation 
processes, suggesting that the control of PAK1 
activity may act as a new and exciting potential 
therapeutic strategy. 
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Figure  legends. 
 
Figure  1. PAK1 upregulates Tissue factor expression. A. Microarray RT-qPCR validation of Tissue 
factor (TF) mRNA expression in the WT and PAK1KO MEFs. The relative mRNA expression levels are 
represented; mouse 18S was used to normalize the values. **, P < 0.001, versus WT MEFs.  B and C. 
The expression of Tissue factor protein (upper panel) and mRNA (lower panel) levels was analyzed after 
serum induction for the indicated times (minutes) in HeLa (B) and MDA-MB-231 cells (C). B and C, 
upper panel. Western blot using phospho-PAK1 (pPAK1), PAK1 and Tissue factor (TF) antibodies. The 
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the 
densitometric values corresponding to the quantification of the bands detected by autorradiography. A 
representative Western blot, from a total of three independent experiments, is shown. B and C, lower 
panel. Total mRNA from HeLa (B) or MDA-MB-231 (C) cells induced with serum for the indicated 
times was analyzed for the expression of Tissue factor (TF) mRNA by RT-qPCR. The relative mRNA 
expression levels are represented; actin expression was used to normalize the values. Each value 
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001 in serum 
stimulated cells compared to non stimulated cells. min: minutes. 
Figure  2. PAK1 is required for the upregulation of Tissue factor by serum. A. Western blot analysis 
of PAK1 and Tissue factor (TF) in HeLa cells transiently transfected with an siRNA against PAK1 
(siPAK1) or an siRNA control (siC) induced with serum for the indicated times (in minutes). The 
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the 
densitometric values corresponding to the quantification of the bands detected by autorradiography. A 
representative Western blot, from a total of three independent experiments, is shown.  B. RT-qPCR 
analysis of Tissue factor (TF) mRNA in WT and PAK1 KO  mouse embryonic fibroblast (MEFs) cells 
induced with serum for the indicated times (in minutes). The relative mRNA expression levels are 
represented; mouse 18S expression was used to normalize the values. Each value represents the mean ± 
S.E. of three independent experiments.*, P<0.005; **, P < 0.001, versus non stimulated WT MEFs. #, 
P<0.005; ##, P < 0.001, versus serum stimulated WT MEFs. C. Western blot (upper panel) and RT-qPCR 
analysis (lower panel) in HeLa cells transiently transfected with the catalytically active (T423E), kinase 
dead (K229R) PAK1 mutants or with the empty vector (CTRL) induced with serum for the indicated 
times. C, upper panel. Cell lysates were blotted with  PAK1 and Tissue factor (TF) antibodies. The 
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the 
densitometric values corresponding to the quantification of the bands detected by autorradiography. A 
representative Western blot, from a total of three independent experiments, is shown.  C, lower panel. 
Total mRNA was analyzed for the expression of Tissue factor (TF) mRNA by RT-qPCR. The relative 
mRNA expression levels are represented; actin expression was used to normalize the values. Each value 
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001, versus non 
stimulated control (CTRL) cells.  #, P<0.005 versus serum stimulated control (CTRL) cells. min: minutes.  
Figure  3. PAK1 is recruited to the promoter of Tissue Factor. A. Schematic representation of the 
promoter of Tissue factor, showing the regions (R) analyzed. B, C. ChIP analysis of the recruitment of 
PAK1 on the hTF promoter in HeLa cells. Negative (Neg) controls, without DNA, are shown for each 
region amplified. Input represents around 1-10% of the total immunoprecipitated DNA. The histogram on 
the right show the densitometric analysis of the bands amplified by PCR. The intensity of the bands 
amplified in the samples immunoprecipitated with IgG was used as the reference and assigned the value 
1. Ab: antibody. 
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Figure  4. c-JUN is involved in the PAK1-mediated regulation of Tissue Factor expression. A. 
EMSA analysis of the binding of GATA-1, PXR-1:RXR-alpha, TCF-4E, AP1/c-JUN, c-ETS, and TFII-I 
transcription factors to the human Tissue Factor promoter using radiolabeled oligonucleotides 
encompassing the predicted consensus binding sites and nuclear extracts from HeLa cells under serum 
starvation/ induction conditions. a and b denote different binding sites predicted for the annotated 
transcription factor. c: control lane without nuclear lysate.+/-: nuclear lysate from HeLa cells induced or 
not with serum, respectively. B. EMSA analysis of c-JUN and PAK1 binding to the human Tissue factor 
promoter using the wild-type (WT) and mutant (MUT) oligonucleotides encompassing c-JUN consensus 
binding sites using HeLa (left panel) or MDA-MB-231 (right panel) nuclear lysates prepared from cells 
stimulated or not with serum. c: control lane without nuclear lysate. +/-: nuclear lysate from HeLa cells 
induced or not with serum, respectively . Ab: Antibody. C. ChIP analysis of the recruitment of c-JUN onto 
the hTF promoter in HeLa cells. R: region. D. Double ChIP analysis of the recruitment of PAK1-c-JUN 
complex onto the Tissue factor chromatin region 1 (R1) and 3 (R3) in HeLa cells. The first ChIP was 
carried out with an anti-PAK1 antibody followed by second ChIP with anti-c-JUN antibody. Negative 
(Neg) controls, without DNA, are shown for each region amplified by ChIP. Input represents around 1-
10% of the immunoprecipitated DNA. E. RT-qPCR analysis of Tissue Factor (TF) mRNA expression in 
HeLa cells transiently overexpressing the catalytically active mutant of PAK1 (T423E), and the dominant 
negative mutant of c-JUN (TAM 67) after serum stimulation for the indicated times (in minutes). The 
relative mRNA expression levels are represented; actin expression was used to normalize the values. Each 
value represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001, versus non 
stimulated T423E PAK1 mutant (T423E) cells.  #, P<0.005 versus serum stimulated T423E PAK1 mutant 
(T423E) cells. min: minutes.  
Figure  5. PAK1 interacts physically with c-JUN.  A. HEK 293T cells were co-transfected with 
expression vectors encoding Flag-c-JUN and Myc-PAK1. Protein extracts were immunoprecipitated (IP) 
with control IgG or an anti- Myc antibody, and were immunoblotted (WB) with the indicated antibodies. 
The input represents around 10% of the total amount of protein used for the immunoprecipitation. B. 
Nuclear protein extracts from HeLa cells were immunoprecipitated with an anti-PAK1 or anti-c-JUN 
antibodies, followed by Western blotting (WB) using the indicated antibodies. C. In vitro transcribed-
translated c-JUN protein (35S-labeled) was incubated with GST or GST-PAK1 constructs. Bound proteins 
were separated and analyzed by SDS-PAGE and autoradiography. D.  In vitro transcribed-translated 
PAK1 protein (35S-labeled) was incubated with GST or GST-c-JUN constructs. Bound proteins were 
separated and analyzed by SDS-PAGE and autoradiography. The lower panels in C and D are Ponceau S-
stained blots showing either GST-PAK1 or GST-c-JUN and GST. The asterisk (*) denotes the presence 
of the GST-PAK1 or GST-c-JUN fusion proteins. 
Figure  6. PAK1 activation regulates the procoagulant activity of Tissue factor. A, B. Monitorization 
of Tissue factor (TF) activity in cell lysates from control HeLa cells (CTRL), or cells transiently 
overexpressing the catalytically active (T423E)(A) and kinase deficient (K229R) (B) PAK1 mutants 
under serum starvation/ induction conditions. The change in absorbance at 405 nm of the released para-
nitroaniline (pNA) chromofore, which is directly proportional to the TF enzymatic activity, was recorded 
each 2 minutes for 20 minutes. The average and standard deviation from three independent experiments is 
shown. Arrows indicate the time points in which the amount of active Tissue Factor was calculated in C.  
C. Amount of active endogenous Tissue Factor (TF) expressed in lysates from control HeLa cells 
(CTRL), or cells transiently overexpressing the catalytically active (T423E) and kinase deficient (K229R) 
mutants of PAK1 under serum starvation/ induction conditions. Values were extrapolated from a standard 
curve generated with different known concentrations of a recombinant human Tissue Factor preparation, 
and expressed as pM of TF per 105 cells. The average and standard deviation from triplicates is shown. *, 
P<0.005; **, P < 0.001 versus non stimulated cells. #, P<0.005 in T423E PAK1 mutant cells (T423E) 
compared to control HeLa cells (CTRL) under serum stimulation conditions. min: minutes. 
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Figure  7. PAK1 downregulates  TFPI mRNA expression by its direct recruitment to the TFPI 
promoter. A. RT-qPCR validation of Tissue factor pathway inhibitor (TFPI) mRNA expression in the 
WT and PAK1 KO MEFs. The relative mRNA expression levels are represented; mouse 18S was used to 
normalize the values. **, P < 0.001, versus WT MEFs. B and C. RT-qPCR analysis of  Tissue factor 
pathway inhibitor (TFPI) mRNA in HeLa (B) and MDA-MB-231 (C) cells after serum induction for the 
indicated times (in minutes). The relative mRNA expression levels are represented; actin expression was 
used to normalize the values. Each value represents the mean ± S.E. of three independent experiments. 
min: minutes. *, P<0.005; **, P < 0.001 in serum stimulated cells compared to non stimulated cells. D. 
RT-qPCR analysis of Tissue factor pathway inhibitor (TFPI) mRNA in WT and PAK1 KO  mouse 
embryonic fibroblast (MEFs) cells induced with serum for the indicated times. The relative mRNA 
expression levels are represented; mouse 18s expression was used to normalize the values. Each value 
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001 in serum 
stimulated cells compared to non stimulated cells. min: minutes. E. RT-qPCR analysis of  Tissue factor 
pathway inhibitor (TFPI) mRNA in HeLa cells transiently transfected with the catalytically active 
(T423E), kinase dead (K229R) PAK1 mutants or with the empty vector (CTRL) induced with serum for 
the indicated times. The relative mRNA expression levels are represented; actin expression was used to 
normalize the values. Each value represents the mean ± S.E. of three independent experiments. *, 
P<0.005; **, P < 0.001, versus non stimulated control (CTRL) cells.  #, P<0.005; ##, P<0.001, versus 
serum stimulated control (CTRL) cells. min: minutes. F. Schematic representation of the promoter of 
Tissue factor pathway inhibitor, showing the regions (R) analyzed by ChIP. G. ChIP analysis of the 
recruitment of PAK1 on the hTFPI promoter in HeLa cells. Negative (Neg) controls, without DNA, are 
shown for each region amplified. Input represents around 1-10% of the total immunoprecipitated 
DNA.Ab: antibody.  H. Schematic representation of TF and TFPI regulation by PAK1. Serum stimulation 
of PAK1 results in the upregulation of TF, by the co-recruitment of PAK1 and c-JUN onto the human TF 
promoter. The upregulation of TF expression by PAK1 is followed by an induction of the procoagulant 
activity of TF. At the same time, serum stimulation of PAK1 results in the downregulation of TFPI 
expression by the co-recruitment of PAK1 and a yet unknown transcription factor onto the TFPI 
promoter, thereby releasing the TF-FVIIa coagulation-initiation complex from its inhibition, and possibly 
contributing to a hypercoagulant state. 
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Table 1. List of the down-regulated or up-regulated genes, involved in thrombosis, in the PAK1 knock-
out  MEFs compared to its wild-type controls. 
refseq Gene 
symbol 
Fold 
change Regulation Gene description 
NM_009378 Thbd 7.86 down thrombomodulin 
NM_011058|NM_001083316 Pdgfra 5.04 down platelet derived growth factor 
receptor, alpha polypeptide 
NM_009255 Serpine2 3.27 down serine (or cysteine) peptidase inhibitor, clade E, member 2 
NM_010171 F3 2.53 down coagulation factor III 
NM_008610 Mmp2 2.51 down matrix metallopeptidase 2 
NM_031168 Il6 2.42 down interleukin 6 
NM_009506 Vegfc 2.37 down vascular endothelial growth factor C 
NM_001110504|NM_007600 Capn1 4.88 up calpain 1 
NM_011576 Tfpi 3.46 up tissue factor pathway inhibitor 
NM_011198 Ptgs2 3.26 up prostaglandin-endoperoxide 
synthase 2 
NM_010217 Ctgf 2.70 up connective tissue growth factor 
NM_008873 Plau 2.25 up plasminogen activator, urokinase 
NM_009931 Col4a1 2.08 up collagen, type IV, alpha 1 
NM_019521 Gas6 2.02 up growth arrest specific 6 
NM_011057 Pdgfb 2.01 up platelet derived growth factor, B polypeptide 
NM_008969 Ptgs1 2.01 up prostaglandin-endoperoxide 
synthase 1 
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Table 2. Complete list of the Transcription factor binding sites predicted in the Tissue factor promoter- 
PAK1 interacting region using Promo 3.0 software analysis. The transcription factors selected for 
electrophoretic mobility shift assay (EMSA) are highlighted. 
 
TRANSCRIPTION 
FACTOR 
Number of 
sites Activator/repressor Function 
TCF-4E [T02878] 2 Activator 
Associated with reduced survival in ER- 
breast cancer cells 
Positive regulation of epithelial cell 
proliferation 
GR [T05076] 1 Activator/repressor Regulation of genes controlling 
development,  
metabolism and immune response 
GR-beta [T01920] 14 Activator/repressor 
GR-alpha [T00337] 7 Activator/repressor 
XBP-1 [T00902] 1 Activator Immune system and cellular stress 
response 
AP-2alphaA 
[T00035] 4 Activator/repressor 
Differentiation and development of neural 
crestal cells 
C/EBPbeta[T00581] 19 Repressor Inflammatory and immune responses 
HOXD9 [T01424] 2 Activator Morphogenesis 
HOXD10 [T01425] 2 Activator Differentiation and limb development  
TFIID [T00820] 1 Activator Basal transcription and transcription initiation 
FOXP3 [T04280] 2 Repressor Immune system responses 
YY1 [T00915] 2 Activator/repressor Proposed core component of chromatin 
remodellin complexes 
GATA-1 [T00306] 2 Activator Platelet agregation and formation Cell growth and cancer 
TFII-I [T00824] 2 Activator/repressor Growth factor signaling. Implications in 
cancer 
HNF-1A [T00368] 1 Activator Liver-specific genes. Glucose homeostasis 
PXR-1:RXR-alpha 
[T05671] 1 Activator/repressor 
Assembly of functional peroxisomes 
(PXR-1). 
Mediator of retinoids (RXR-alpha) 
c-Ets-1 [T00112] 1 Activator/repressor Stem cell development, cell senescence 
and death, and tumorigenesis 
STAT4 [T01577] 1 Activator 
Mediation of cellular responses to IL-12 in 
T-lymphocites 
Signaling molecule for TH1 differentiation 
AP-1 [T00029] 1 Activator Differentiation, proliferation and apoptosis 
c-Jun [T00133] 1 
LEF-1 [T02905] 1 Activator Wnt signaling 
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